Translations:GLP1 poly-agonist peptides/4/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 22:01, 2 April 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (GLP1 poly-agonist peptides)
==GLP-1, GIP, and glucagon receptor triple agonists==
Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits. A clinical trial of the triple agonist [[retatrutide]] found an average −24.2 percent weight reduction in the highest dosage group after 24 weeks.

GLP-1, GIP, and glucagon receptor triple agonists

Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits. A clinical trial of the triple agonist retatrutide found an average −24.2 percent weight reduction in the highest dosage group after 24 weeks.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:GLP1_poly-agonist_peptides/4/en&oldid=133034"